Press releaseGlobe Newswire
Legend Biotech
LEGN · NASDAQ
$19.01+$0.36 (+1.93%)TodayMarket closed ·
Prev close $18.65
Latest news
- Press releaseGlobe Newswire
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
- Press releaseGlobe Newswire
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
- Press releaseGlobe Newswire
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
- Press releaseGlobe Newswire
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
- News
Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate
- Press releaseGlobe Newswire
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
- Press releaseGlobe Newswire
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
- Press releaseGlobe Newswire
Legend Biotech Announces CEO Transition
- NewsVandana Singh
Why Is Legend Biotech Stock Falling Thursday?
- NewsAvi Kapoor
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- News
10 Health Care Stocks Whale Activity In Today's Session
- Press releaseGlobe Newswire
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
- Press releaseGlobe Newswire
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
- NewsAvi Kapoor
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
- News
Legend Biotech Q1 2026 Earnings Call Transcript
- News
Earnings Scheduled For May 12, 2026
- Press releaseGlobe Newswire
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
- Press releaseGlobe Newswire
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
- News
An Overview of Legend Biotech's Earnings
- News
What to Expect from Legend Biotech's Earnings
- Press releaseGlobe Newswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
- News
'Legend Biotech Is Said to Explore Second Listing Outside of US'- Bloomberg
- Press releaseGlobe Newswire
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
- Press releaseGlobe Newswire
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results
- NewsVandana Singh
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
- Press releaseGlobe Newswire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
- Press releaseGlobe Newswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
- Press releaseBusiness Wire
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech
- Press releasePRNewswire
GenScript Subsidiary Legend Biotech Achieves Breakthrough with Cilta-cel Approval in China, Offering New Hope for Multiple Myeloma Patients
- NewsThe Bamboo Works
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
- NewsLekha Gupta
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
- NewsAvi Kapoor
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.